The liver cirrhosis treatment market is poised for significant growth, driven by the rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors like obesity, alcohol consumption, and metabolic syndrome. Technological advancements in antiviral therapies and regenerative medicine are enhancing treatment outcomes, while an aging population further increases demand. These factors collectively highlight a strong growth trajectory for the market.
New York, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) — Liver Cirrhosis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain
The liver cirrhosis treatment market is poised for significant growth, driven by the rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors like obesity, alcohol consumption, and metabolic syndrome. Technological advancements in antiviral therapies and regenerative medicine are enhancing treatment outcomes, while an aging population further increases demand. These factors collectively highlight a strong growth trajectory for the market.
DelveInsight’s ‘
A snapshot of the Pipeline Liver Cirrhosis Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Elafibranor | Ipsen | III | Peroxisome proliferator-activated receptor alpha, delta agonists | Oral |
| Volixibat | Mirum Pharmaceuticals | III | Sodium-bile acid cotransporter inhibitors | Oral |
| GXHPC1 | Gwo Xi Stem Cell Applied Technology | II | Cell replacements | Intrahepatic |
| RTX-001 | Resolution Therapeutics | II | Macrophage replacements | Intravenous |
| PHIN-214 | PharmaIN | I | Vasopressin 1a receptor agonists | Subcutaneous |
Learn more about the emerging liver cirrhosis therapies @ Liver Cirrhosis Clinical Trials
Liver Cirrhosis Therapeutics Assessment
The liver cirrhosis pipeline report proffers an integral view of the emerging liver cirrhosis therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Liver Cirrhosis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: Sodium-bile acid cotransporter inhibitors, Regulatory T-lymphocyte stimulants, Ammonia scavengers, DNA gyrase inhibitors, DNA topoisomerase inhibitors, DNA-directed RNA polymerase inhibitors, Beta-catenin inhibitors, CREB-binding protein inhibitors, Wnt signalling pathway inhibitors, Bacteria replacements, Microbiome modulators
- Key Liver Cirrhosis Companies: Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Intercept Pharmaceuticals, Boehringer Ingelheim, Ohara Pharmaceutical, Ocelot Bio, Calliditas Therapeutics, Galecto Biotech, Pharmicell, and others.
- Key Liver Cirrhosis Pipeline Therapies: Volixibat, VS-01, TVB-2640, TNP-2092, PRI-724, VE303, Obeticholic Acid (OCA), BI 685509, OP-724, OCE-205, GKT137831, GB1211, Cellgram-LC, and others.
Dive deep into rich insights for new liver cirrhosis treatments, visit @ Liver Cirrhosis Drugs
Table of Contents
| 1. | Liver Cirrhosis Pipeline Report Introduction |
| 2. | Liver Cirrhosis Pipeline Report Executive Summary |
| 3. | Liver Cirrhosis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Liver Cirrhosis Clinical Trial Therapeutics |
| 6. | Liver Cirrhosis Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Liver Cirrhosis Pipeline: Late-Stage Products (Phase III) |
| 8. | Liver Cirrhosis Pipeline: Mid-Stage Products (Phase II) |
| 9. | Liver Cirrhosis Pipeline: Early-Stage Products (Phase I) |
| 10. | Liver Cirrhosis Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Liver Cirrhosis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Liver Cirrhosis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the liver cirrhosis pipeline therapeutics, reach out @ Liver Cirrhosis Therapeutics
Related Reports
Liver Cirrhosis Epidemiology Forecast
Liver Cirrhosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted liver cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver cirrhosis companies, including Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, CymaBay Therapeutics, Akero Therapeutics, Inc., NGM Biopharmaceuticals, Inc., Gilead Sciences, Novo Nordisk A/S, Cellaion, Promethera Therapeutics, Lipocine Inc., Bristol Myers Squibb, Prism Pharma, Ohara Pharmaceutical, Shionogi, Rohto, among others.
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced hepatocellular carcinoma with CPB liver cirrhosis companies, including Can-Fite Biopharma, among others.
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Market
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced hepatocellular carcinoma with CPB liver cirrhosis companies, including Can-Fite Biopharma, among others.
Hearing Loss Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hearing loss companies, including Acousia Therapeutics, Decibel Therapeutics, Otonomy Inc., Sensorion, Autifony Therapeutics, Auris Medical, Sound Pharmaceuticals, Anida Pharma Inc., Gateway Biotechnology, Myrtelle Inc., Lineage Cell Therapeutics, Inc., Altamira Therapeutics, Hoba Therapeutics, Rinri Therapeutics, Autifony Therapeutics, Otologic Pharmaceutics, Audion Therapeutics, Perha Pharmaceuticals, Applied Genetic Technologies Corporation, Akouos, Inc., Oricula Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Prime Medicine, Boehringer Ingelheim, Autigen, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Astellas Pharma, Mogrify Limited, among others.
Nonalcoholic Steatohepatitis Market
Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, Cirius Therapeutics, among others.
Non-Alcoholic Fatty Liver Disease Market
Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com
The post Liver Cirrhosis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain first appeared on CXP – Customer Experience Asia.
